4.3 Review

Role of the CXCR4/CXCL12 signaling axis in breast cancer metastasis to the brain

Journal

CLINICAL & EXPERIMENTAL METASTASIS
Volume 27, Issue 2, Pages 97-105

Publisher

SPRINGER
DOI: 10.1007/s10585-008-9210-2

Keywords

AKT; AMD3100; Breast cancer; CNS; CXCL12; CXCR4; Endothelial cells; HER2; Metastasis; PI-3K; VEGF

Categories

Funding

  1. National Institutes of Health [HL80699, CA096805, HL00791708]
  2. Susan G. Komen Fellowship

Ask authors/readers for more resources

Breast cancer is the most common malignancy and second leading cause of cancer death in women. Ninety percent of mortality in breast cancer is often associated with metastatic progression or relapse in patients. Critical stages in the development of aggressive breast cancer include the growth of primary tumors and their ability to spread to foreign organs and form metastases, as well as the establishment of an independent blood supply within the new tumors. Hence, it is imperative to characterize the key molecules that regulate the metastasis of human breast cancer cells. The expression of CXCR4/CXCL12 in breast tumors has been correlated with a poor prognosis, increased metastasis, resistance to conventional therapeutic agents and a poor outcome in the pathogenesis of breast cancer. However, effective anti-CXCR4 therapy remains a challenge. Here, we will review the putative involvement of the CXCR4/CXCL12 signaling axis in breast cancer metastasis to the brain. Characterization of signaling events important for breast cancer cell growth and their metastasis to the brain should provide insights into breast cancer therapies and improved, successful treatments for breast cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available